Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

751
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

697
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.2K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced Myocardial Serine Synthesis Impairs Functional, Metabolic, and Redox Adaptations to Cardiac Stress.

bioRxiv : the preprint server for biology·2026
Same author

YAP mediates activation of the serine synthesis pathway in the heart during pressure overload.

Journal of molecular and cellular cardiology·2026
Same author

Single-Cell Analysis of Human Heart Failure With Preserved Ejection Fraction.

Circulation research·2026
Same author

MitoSAM-dependent lipoylation controls postnatal heart development via metabolic remodeling.

bioRxiv : the preprint server for biology·2026
Same author

Severe obesity in human HFpEF alters contractile protein function and organization.

Science (New York, N.Y.)·2026
Same author

Emerging therapeutic directions for inotropic therapy in heart failure.

Med (New York, N.Y.)·2026

Related Experiment Video

Updated: Mar 28, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Pacemaker-induced transient asynchrony suppresses heart failure progression.

Jonathan A Kirk1, Khalid Chakir1, Kyoung Hwan Lee2

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Science Translational Medicine
|December 25, 2015
PubMed
Summary

Pacemaker-induced transient asynchrony (PITA) improves heart failure by temporarily inducing dyssynchrony, offering a new therapy for patients ineligible for cardiac resynchronization therapy (CRT). This novel approach benefits hearts with synchronous contractions, unlike traditional CRT.

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.7K

Related Experiment Videos

Last Updated: Mar 28, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K
Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.7K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Heart Failure Pathophysiology

Background:

  • Uncoordinated heart contractions (electromechanical delay) worsen heart failure. Cardiac resynchronization therapy (CRT) improves heart failure by coordinating contractions but isn't suitable for all patients.
  • Heart failure can present with synchronous contractions, a condition not currently addressed by CRT.

Purpose of the Study:

  • To investigate the efficacy of pacemaker-induced transient asynchrony (PITA) in improving heart failure with synchronous contractions.
  • To determine if PITA can offer an alternative therapeutic strategy for heart failure patients ineligible for CRT.

Main Methods:

  • A canine model of heart failure was established using atrial tachypacing.
  • PITA was implemented by daily 6-hour right ventricular pacing in heart failure dogs.
  • Physiological and cellular responses, including cardiac function, β-adrenergic responsiveness, and myocyte structure, were assessed.

Main Results:

  • PITA suppressed progressive cardiac dilation and improved chamber and myocyte dysfunction in heart failure dogs.
  • PITA enhanced in vivo β-adrenergic responsiveness and normalized myocyte function.
  • Beneficial effects were dependent on the continuity of dyssynchrony exposure, not random pacing.

Conclusions:

  • PITA demonstrates potential as a novel treatment for heart failure patients with synchronous contractions who are not candidates for CRT.
  • The findings suggest that transiently induced dyssynchrony can trigger beneficial biological responses leading to improved cardiac function.
  • PITA offers a promising new avenue for managing heart failure by leveraging controlled asynchrony.